David Endicott

“In the third quarter, we grew sales 5%, bringing year-to-date growth to 6%. We remain on track to deliver on our full-year guidance of approximately 6% sales growth and double-digit core EPS growth, despite some specific areas of competitive pressure.”

“Our second quarter results demonstrate the strength of our new products and the benefits of our innovation investments. We delivered 7% sales growth, which was broad-based across both franchises and geographies, reinforcing the impact of our diverse portfolio and our commercial reach.”

“Let me start by recognizing the incredible work of our talented teams around the world. Your ongoing dedication, innovation, and commitment to our customers continue to move Alcon forward and make a meaningful difference in patients' lives.”

“Before we begin, I want to express my appreciation to more than 25,000 associates. Your commitment to customers, your passion for innovation, and your resilience continues to fuel our performance.”

“We entered 2025 knowing that it would be a year of building toward the second half, and the third quarter reflects that progress. While there's still work ahead, we're encouraged by the momentum we're seeing in equipment and ocular health.”